{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$4.86 vs. cons $4.79",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Enterprise Revenue (Q2 2026)",
      "prediction": "IN-LINE",
      "answer": "pred ~$3.75B vs. cons $3.72B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Diagnostics Organic Volume Growth (Q2 2026)",
      "prediction": "MISS",
      "answer": "pred ~1.3% vs. cons ~2.2% implied organic volume growth",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$18.00-$18.50 (mid $18.25) vs. cons $18.20 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Enterprise Revenue Growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~5.2%-6.2% (mid 5.7%) vs. cons 5.8% (FY2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "BLS Book-to-Bill sequential improvement (Q2 2026)",
      "prediction": "BETTER",
      "answer": "guide/actual ~1.02x vs. cons/prior-quarter 0.94x (Q2 2026, trailing-12mo ~1.05x)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 0.7,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -0.4,
  "day5_path": "FADE",
  "day5_rationale": "Stock has already run up ~18% YTD and sits near consensus price targets, so even a clean beat-and-raise is largely priced in; a modest EPS beat paired with only an in-line/soft Diagnostics organic volume print (ACA/HCA read-through risk) and a guidance raise that likely keeps the low end unchanged (implicit back-half conservatism) gives sell-side limited room to raise out-year numbers meaningfully. Expect an initial small pop on the beat that fades over the week as analysts digest ACA volume commentary, PAMA/RESULTS Act overhang, and profit-taking after the recent rally, unless BLS book-to-bill and Central Labs commentary are unusually strong.",
  "day5_confidence": "MEDIUM"
}